Anaplastic thyroid cancer (ATC) is a lethal human cancer with a 5-year survival rate of less than 10%. Recently, its genomic and transcriptomic characteristics have been extensively elucidated over 5 years owing to advance in high throughput sequencing. These efforts have extended molecular understandings into the progression mechanisms and therapeutic vulnerabilities of aggressive thyroid cancers. In this review, we provide an overview of genomic and transcriptomic alterations in ATC and poorly-differentiated thyroid cancer, which are distinguished from differentiated thyroid cancers. Clinically relevant genomic alterations and deregulated signaling pathways will be able to shed light on more effective prevention and stratified therapeutic interventions for affected patients.

Citations

Citations to this article as recorded by  

• The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
  Peter Y.F. Zeng, Stephenie D. Prokopec, Stephen Y. Lai, Nicole Pinto, Michelle A. Chan-Seng-Yue, Roderick Clifton-Bligh, Michelle D. Williams, Christopher J. Howlett, Paul Plantinga, Matthew J. Cecchini, Alfred K. Lam, Iram Siddiqui, Jianxin Wang, Ren X.
  Cell Reports.2024; 43(3): 113826.     CrossRef
• Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation
  Kun Zhang, Xinyi Wang, Tao Wei, Zhihui Li, Jingqiang Zhu, Ya-Wen Chen
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer – Real-World Outcomes From UK Centres
  C. Lorimer, L. Cheng, R. Chandler, K. Garcez, V. Gill, K. Graham, W. Grant, S. Sardo Infirri, J. Wadsley, L. Wall, N. Webber, K.H. Wong, K. Newbold
  Clinical Oncology.2023; 35(1): e60.     CrossRef
• MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions
  E. Macerola, A. M. Poma, P. Vignali, A. Proietti, L. Torregrossa, C. Ugolini, A. Basolo, A. Matrone, R. Elisei, F. Santini, F. Basolo
  Journal of Endocrinological Investigation.2023; 46(8): 1651.     CrossRef
• RBX1 regulates PKM alternative splicing to facilitate anaplastic thyroid carcinoma metastasis and aerobic glycolysis by destroying the SMAR1/HDAC6 complex
  Debin Xu, Jichun Yu, Yuting Yang, Yunyan Du, Hongcheng Lu, Shouhua Zhang, Qian Feng, Yi Yu, Liang Hao, Jun Shao, Leifeng Chen
  Cell & Bioscience.2023;[Epub]     CrossRef
• Multi-Omics and Management of Follicular Carcinoma of the Thyroid
  Thifhelimbilu Emmanuel Luvhengo, Ifongo Bombil, Arian Mokhtari, Maeyane Stephens Moeng, Demetra Demetriou, Claire Sanders, Zodwa Dlamini
  Biomedicines.2023; 11(4): 1217.     CrossRef
• Genomic landscape of anaplastic thyroid cancer and implications on therapy
  Leslie Cheng, Kate Newbold
  Current Opinion in Endocrine and Metabolic Research.2023; 30: 100458.     CrossRef
• Modeling the tumor microenvironment of anaplastic thyroid cancer: an orthotopic tumor model in C57BL/6 mice
  Zhen Xu, Hyo Shik Shin, Yoo Hyung Kim, Seong Yun Ha, Jae-Kyung Won, Su-jin Kim, Young Joo Park, Sareh Parangi, Sun Wook Cho, Kyu Eun Lee
  Frontiers in Immunology.2023;[Epub]     CrossRef
• Characterization of the genomic alterations in poorly differentiated thyroid cancer
  Yeeun Lee, SeongRyeol Moon, Jae Yeon Seok, Joon-Hyop Lee, Seungyoon Nam, Yoo Seung Chung
  Scientific Reports.2023;[Epub]     CrossRef
• Genetica del carcinoma anaplastico della tiroide
  Teresa Ramone, Chiara Mulè, Cristina Romei, Raffaele Ciampi, Eleonora Molinaro, Rossella Elisei
  L'Endocrinologo.2022; 23(2): 208.     CrossRef
• Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology
  Elena Muraro, Rebecca Romanò, Giuseppe Fanetti, Emanuela Vaccher, Irene Turturici, Valentina Lupato, Fabio Biagio La Torre, Jerry Polesel, Elisabetta Fratta, Vittorio Giacomarra, Giovanni Franchin, Agostino Steffan, Michele Spina, Salvatore Alfieri
  Critical Reviews in Oncology/Hematology.2022; 175: 103707.     CrossRef
• Recent Improvements in the Treatment of High-Risk Thyroid Cancer
  Eun Kyung Lee
  Korean Society for Head and Neck Oncology.2022; 38(1): 1.     CrossRef
• Inhibition of Glycogen Metabolism Induces Reactive Oxygen Species-Dependent Cytotoxicity in Anaplastic Thyroid Cancer in Female Mice
  Cole D Davidson, Jennifer A Tomczak, Eyal Amiel, Frances E Carr
  Endocrinology.2022;[Epub]     CrossRef
• Survival prognostic factors for differentiated thyroid cancer patients with pulmonary metastases: A systematic review and meta-analysis
  Hao Zhao, Chun-Hao Liu, Yue Cao, Li-Yang Zhang, Ya Zhao, Yue-Wu Liu, Hong-Feng Liu, Yan-Song Lin, Xiao-Yi Li
  Frontiers in Oncology.2022;[Epub]     CrossRef
• 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
  Keith C. Bible, Electron Kebebew, James Brierley, Juan P. Brito, Maria E. Cabanillas, Thomas J. Clark, Antonio Di Cristofano, Robert Foote, Thomas Giordano, Jan Kasperbauer, Kate Newbold, Yuri E. Nikiforov, Gregory Randolph, M. Sara Rosenthal, Anna M. Saw
  Thyroid.2021; 31(3): 337.     CrossRef
• Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine
  Antonio Ieni, Roberto Vita, Cristina Pizzimenti, Salvatore Benvenga, Giovanni Tuccari
  Journal of Personalized Medicine.2021; 11(5): 333.     CrossRef
• The Role of Altered Mitochondrial Metabolism in Thyroid Cancer Development and Mitochondria-Targeted Thyroid Cancer Treatment
  Siarhei A. Dabravolski, Nikita G. Nikiforov, Alexander D. Zhuravlev, Nikolay A. Orekhov, Liudmila M. Mikhaleva, Alexander N. Orekhov
  International Journal of Molecular Sciences.2021; 23(1): 460.     CrossRef
• Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E
  Young Shin Song, Young Joo Park
  Endocrinology and Metabolism.2020; 35(3): 515.     CrossRef